Olivier Jarry Email and Phone Number
New York, NY, US
Olivier Jarry's Location
New York, New York, United States, United States
Olivier Jarry's Contact Details
Olivier Jarry work email
- Valid
- Valid
- Valid
- Valid
- Valid
Olivier Jarry personal email
n/a
Olivier Jarry phone numbers
About Olivier Jarry
Olivier leverages 35+ years of passion improving health and living standards throughout Western / Eastern Europe, the Americas, India, Asia - delivers top / bottom line growth (P&L up to USD 1.4 billion),- starts new businesses (up to USD 0.8 billion), - concludes M&A transactions (up to USD 1.1 billion, 16+ successful post-merger integrations), - drives large enterprise transformations / turnarounds, - innovates with digital technologies, - orchestrates strategic planning, strategic marketing, business development (up to USD 6 billion)- raises funds for biotech, medtech (USD 40+ million to date)Boards: • Imagiance LLC (dba 3xBL Enterprises)- Principal• Fit4D – Board Member, Advisor (adherence coaching for people with diabetes)• MergerWorks – Advisor (M&A consulting)• Foundation Ventures – Advisor (investments)• Atlas Advisors – Advisor (investments)• NYU Marketing Committee – Board member (education)• Executive Forum – Board member (prof. association)• AdvaMed Dx – former Board member (prof. association)• AFNOR/ISO – former committee member on Project Management standardizationSpecialties: Organic Growth | Turnarounds | Corporate Mergers & Acquisitions (M&A) | Post-Merger Integration (PMI) | Corporate Strategy | Strategic Planning / Operations Planning / Business Planning | Alliances and Joint-Ventures | Business Development | Start-Ups | Funding | Exit Strategies | Angel Investor / Venture Capital (VC) / Private Equity (PE) | New Products / launches | New Sales Channels / Markets | Emerging Markets | Bottom-Of-the-Pyramid ("BOP") | For-profit | Non-for-profit Boards | Multiple Expansion | Revenue Acceleration | Margin Enhancement | EBITDA Improvement | P&L Responsibility | Global Chief Operating Officer (COO) | International Senior Vice-President (SVP) | Pharmaceuticals (Rx) | Generics (Gx) | Vaccines (Vx) | Medical Devices / Diagnostics (Dx) | Over The Counter medicines (OTC) | Treatment Adherence / Behavior Change (Bx) | FMCG / CPG / Consumer Products | Industrial Products | Electronics / Automation | Fortune 50 | B2C | B2B
Olivier Jarry's Current Company Details
Liberabio
View
Chief Executive Officer and Co-Founder
New York, NY, US
- Website:
- liberabio.com
- Employees:
- 10
Olivier Jarry Work Experience Details
-
Chief Executive Officer And Co-FounderLiberabioNew York, Ny, Us
-
Ceo And Co-FounderLiberabio Apr 2018 - PresentSantiago De Compostela, Galicia, EsSupporting the organization and development of this pre-clinical oncology company that has patented the MPN Technology for the actively-targeted delivery of biologics (and small molecules) to tumor and metastatic cells, and even more importantly to intracellular oncoproteins (such as KRAS), until now considered "undruggable". Several assets co-developed with global pharma and biotech companies.
-
CooAdvantage Therapeutics Inc. May 2023 - PresentMiami, Florida, UsADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter. -
CfoRational Vaccines Aug 2021 - PresentWoburn, Massachusetts, UsRational Vaccines develops therapeutic and prophylactic vaccines against herpes simplex viruses HSV-1 and HSV-2. These vaccines are based on engineered live attenuated viruses designed for safety and immunogenicity. 4+ billion individuals are estimated seropositive to herpes, which may manifest itself as breakouts, neuropathy or even encephalopathy. Studies have linked HSV-1 to brain inflammation and neurodegeneration. -
Non Executive DirectorOs Therapies Oct 2024 - PresentNew York, Ny, UsOS Therapies (OST) is a clinical-stage cancer immunotherapy company dedicated to developing a new way of activating the immune system to kill cancers that express HER2 like Osteosarcoma, Breast Cancer, Colorectal Cancer and other solid tumors. With over 30 years of without new treatments in Osteosarcoma, we are first addressing this urgent need for innovative therapies for both kids and adults.We will then expand our lead candidate’s therapeutic development into Breast, Esophageal, Lung, Ovarian, and Pancreatic cancers. -
Managing DirectorAtlas Advisors, Llc Apr 2020 - PresentNew York, New York, UsAtlas Advisors provides its clients with advisory capabilities across North America, Europe, Latin America and Asia.Drawing on the deep and broad experience of our professionals, we are active across the full range of M&A advisory roles, including acquisitions, mergers, joint ventures, minority investments, asset swaps, divestitures, distressed sales, capital raising and financing from strategic and financial investors. -
Member (Formerly On Board)Executive Forum Apr 2011 - Dec 2023New York, Ny, Us -
Board Member Ny/NjAmerican Diabetes Association Apr 2019 - Dec 2021Arlington, Va, Us -
Managing Partner - Life Sciences, Market Research, Global Access-To-Medicines, SdgImagiance Llc (Dba 3Xbl) Jan 2011 - Oct 2021Larchmont, New York, Us- PHYSICIAN ENGAGEMENT. Processes and systems to develop physicians personally and professionally.- PATIENT ENGAGEMENT. Processes and systems to improve health outcomes and satisfaction for patients, while containing costs for the healthcare system ("triple aim").- ACCESS TO HEALTHCARE. Design and implement programs to increase access to healthcare for low income patients (GSK, Pfizer). Public-Private Partnerships (PPP). Collaboration with Non-Governmental Organizations (NGOs). Co-author of access to medicines study (http://www.medicines-for-bop.net/report/) with www.endeva.org and the German Government, and of a white paper about branded generics with Accenture.- BUSINESS DEVELOPMENT & STRATEGY CONSULTING. Angel Investor and coach for biopharma/biotech start-ups. Evaluation and due diligence for acquisitions and divestitures in biotech and medtech. Post-Merger Integration (with www.MergerWorks.com). International Commercialization and Market Access consulting (Americas, Europe, China). “Beyond The Pill” / Integrated Care strategies. Digital health. -
MemberForbes Councils Jan 2020 - Dec 2020Boston, Massachusetts, Us -
President & Chief Commercial OfficerDariohealth Corp. Sep 2018 - Apr 2020New York, New York, UsLaunched B2B channels for Dario: Employers, Payers, Healthcare Providers, Drugstores, as well as several alliances with large organizations. -
Senior Adviser - Business Development & AlliancesDariohealth Corp. Nov 2016 - Apr 2020New York, New York, UsDarioHealth Corp. (NASDAQ:DRIO) is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people with chronic condition manage their health.By delivering personalized evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth has developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way.
-
Senior Advisor (Investment Banking, Life Sciences)Columbia Capital Securities Jul 2017 - Apr 2020Investment banking in biotechnology, medical technology, digital health. (FINRA registered Series 7, 63, 79)
-
Non-Executive Director (Board Member) - Business Development & AllianceLifnano Therapeutics Nov 2016 - Apr 2019Cambridge, GbLIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF).Following the Founder's discovery that LIF is of profound importance in immune self-tolerance in addition to the known key role of LIF in stem cells and tissue maintenance, the therapeutic potential of LIF has been harnessed by invention of a targeted delivery platform using nanotechnology in collaboration with Yale University. After extensive proof of concept that our nano-formulated LIF is safe and efficacious, LIFNano Therapeutics is now taking LIF to patients. CEO 2016-2018 -
Chief Executive OfficerLifnano Therapeutics Nov 2016 - Aug 2018Cambridge, Gb
-
Senior Adviser - Pharmaceuticals Consulting, Market Access, Product Launches, Health EconomicsEnterprise Analysis Corporation Jun 2014 - Aug 2018Stamford, Ct, UsStrategic Planning. Health economics. Outcomes studies (retrospective, prospective, predictive). Value of diagnostics. -
Advisory Board MemberFit4D, Personalized Diabetes Coaching Jan 2013 - Aug 2018New York, New York, UsBusiness development. -
Partner Skipta GlobalSkipta Aug 2013 - Dec 2017New York, Ny, UsExpanding internationally a universe of social networks that allow verified healthcare professionals to collaborate with each other within their medical specialty, and life sciences companies to engage in a dialogue with them.Exit via divestiture to Informa plc. -
Svp Consumer SectorIntrexon Corporation May 2015 - Jan 2016Germantown, Maryland, Us"Whether engineering novel therapies for health, delivering unique solutions to address global energy demand, enabling unparalleled productivity advancements in food, or developing innovative applications in the consumer and environment sectors, Intrexon is working diligently today to create a better tomorrow.” -
Head Strategy, Operations, Market Access / Emerging MarketsBristol-Myers Squibb Sep 2011 - Oct 2012Lawrence Township, Nj, Us- Led Commercial Operations for a USD 1 billion division with fast growing, innovative medicines- Updated 10-year strategy for exponential growth. Local alliances and acquisitions. - Evaluated new pricing approaches such as tier pricing and enhanced Patient Accessibility Programs (PAPs).- Re-launched the Market Access function for Emerging Markets - Oncology, Virology, Immunology, Metabolism, CVS and CNS. Introduced or strengthened Patient Support Programs in cooperation with local third parties in several countries.- Turkey and Russia. Supported strengthening Market Access function and strategies to address forced price reductions in Turkey and regulations severely limiting access to HCPs in both countries.- Brazil. Redefined 5-year plan, reorganized Market Access in Brazil, supported public-private partnerships. Prepared the teams for numerous launches within 18 months.- India. Refined strategy and access based on new challenges (compulsory licensing threats, PAPs, discounts based on income, micro finance).- China. Defined 2021 vision with country president and team. -
Global Division Head - Diabetes CareBayer Healthcare Jun 2009 - Nov 2010Leverkusen, North Rhine-Westphalia, De- Led sustainable, profitable growth in all regions for a USD 1.5 billion business unit. Evaluated new ways to reach the market / create new market segments. Aligned the portfolio of products and services to new strategies. Explored possible partnerships, alliances, acquisitions. Adapted the talent pool.- Launched five acclaimed (New York Times, Wall Street Journal) new products and gained market share in most markets. - Introduced Market Access methodology (derived from Pharma) to prepare for the global launch of a new Continuous Glucose Monitoring (CGM) device.- Negotiated and implemented a new alliance with Medtronic to jointly access users of insulin pumps.- North America. Re-evaluated profitability by channel. Established new guidelines for negotiation with Payers. Engaged with US FDA on blood glucose meters accuracy standards.- Europe. Became #2, passing Johnson & Johnson.- Asia. Re-organized China and the region. Supported expansion to South East Asia through distributors.- Led plan to drastically reduce costs in all areas and re-structure the entire business, in coordination with Division President. -
Head Western/Eastern Europe, Vaccines (Incl. Russia, Cis)Novartis Aug 2008 - Jun 2009Basel, Baselstadt, Ch- Grew the vaccines market share in more than 30 countries. Addressed the requests for H1N1 pandemic flu vaccines from numerous governments.- Restructured the region for its next phase of growth, including new launches, while maintaining internal headcount to the minimum.- Created regional Market Access function. Designed Market Access methodology derived from the Novartis Pharma methodology.- Supported Access teams regarding seasonal and pandemic flu across the region. Personally involved with several government for their procurement of H1N1 pandemic flu vaccine.- Directly negotiated Access for a "pre-market-approval" vaccine to address a meningitis outbreak. - Created Access for a new, sensitive tuberculosis test in Russia, in collaboration with local hospitals.- Prepared local teams for rapid growth. Organized new management teams in strategic countries. Expanded partnerships with distributors. Analyzed opportunities for external growth and partnerships. Anticipated the launch of future “blockbuster” products. -
Head, Arogya Parivar (Implementing For-Profit Social Business Model In India)Novartis Jul 2006 - Jul 2008Basel, Baselstadt, Ch- Designed and implemented a then unique for-profit business model to improve access to medicines in low-income markets of rural India, a CEO-backed initiative involving new products, new distribution, face-to-face marketing, alliances with NGOs and local healthcare players. (http://www.youtube.com/watch?v=o6nS8gBM_WQ)- Introduced 70 medicines in 9 therapeutic areas, along with awareness / affordability / availability programs. Led the design of several products specifically for this channel.- After two years, 25 million villagers were served in more than 50 locations throughout four Indian states, with medicines addressing conditions from anemia to tuberculosis- Participated in shaping a new division to better address developing countries.
-
Senior Vp Strategy, Business Development & Licensing - Head Asia-Pacific - Head Consumer ExcellenceNovartis May 2004 - Jul 2006Basel, Baselstadt, Ch- Supported the growth of a USD 1.5 billion division through M&A, JV's, alliances, various agreements (co-manufacturing, technology in- and out- licenses, distribution...)- Developed strategic plans for division and group executive committees, that ultimately led to a divestiture of the division to Nestlé. - Managed Asia region. Created or expanded partnerships in China and Japan to facilitate local manufacturing and marketing of baby nutrition products and baby accessories.- Led Consumer Excellence for the Division, the marketing best practices and development program of Novartis Consumer Health
-
Senior Vp Latin America (I&B Division)Novartis Apr 2002 - May 2004Basel, Baselstadt, Ch- Grew all markets in Latin America (US$ 250 million baby jars and cereals, baby accessories) and achieved record market shares in each country and segment, despite a very depressed economy in the continent, falling consumer purchasing power, diminishing births and intensified competition - Simplified organization from 7 sub-regions to 3 and implemented leaner organization (3000 associates, 4 plants). Simplified product portfolio. Expanded partnerships (Disney).- Worked with Mexican MOH to optimize supplementation in baby nutrition and obtain an endorsement from pediatrician associations. Designed low-price cereals and purees for low income segment (under new brand). As a result, sales from new products soared, changing category dynamics from -13% to +14% in traditional stores.
-
Vp And Gm Brazil, Argentina, ChileNovartis Jul 2001 - Mar 2002Basel, Baselstadt, Ch- Developed all Consumer Health activities in Argentina, Brazil, Chile, Paraguay, Uruguay (US$100 million baby products, over-the-counter (OTC) drugs, medical nutrition, functional foods).- Turned around the Brazilian business after years of losses. Consolidated plants. Divested non-core businesses. Grew Medical Nutrition and OTC businesses by mid-double-digit with new, local manufacturing of liquid ready-to-use nutrition product, pain management spray and patch.
-
Director Business Development & Strategy WorldwideNovartis Feb 2001 - Jul 2001Basel, Baselstadt, ChDefined, organized and ran the 2002-2006 worldwide Strategic Plan for the Division (US$ 6 billion). Led numerous projects of acquisitions, divestitures and licensing (Poland, Brazil, Germany, France).
-
Vp M&A, Strategy - Worldwide Beverages DivisionDanone Sep 1999 - Feb 2001Paris, FrCoordinated the 2001-2005 Strategic Plan for the Worldwide Water Division (US$ 3 billion) and defined global strategies. Initiated and led alliances and acquisitions in Canada, the USA, Mexico, Brazil, Uruguay, Argentina, Portugal and Italy. -
Cfo - Vp Finance, Strategy, M&A, Customer Service, It, Logistics (Usa, Canada)Danone Jan 1996 - Sep 1999Paris, FrContributed to grow the US and Canadian sales from US$ 250 millions to US$ 600 millions through organic growth and 3 successfully integrated acquisitions (AquaPenn Spring Water, McKesson Water Products, Naya)
-
Associate Partner, Industrial & Consumer ProductsAccenture Sep 1984 - Jan 1996Dublin 2, Ie- Sold, designed and implemented consulting engagements related to major transformations in multinational companies, predominantly in the mechanical and electronics industries (strategic analysis, business process reengineering (BPR), design and implementation of information systems, change management, M&A). Specialized in profitability turnaround, mergers & acquisitions, launch of new activities- DANONE. Creation of the International Division, selling in 65 countries.- GENERAL ELECTRIC MEDICAL SYSTEMS - EUROPE. Reengineering of Finance and Business Planning into a single location for all European operations, saving very significant costs.- SCHNEIDER ELECTRIC. Post-Merger Integration (PMI) of 6 acquisitions worldwide. Global design and implementation of a new worldwide strategic planning and business planning process, of a new cost accounting system .Reorganization of the German subsidiary.- SNCF (French Railways). Led the 1995-2000 Strategic Plan (“Contrat de Plan”, USD 20 billion investments - approved by the Minister of Transportation and implemented in the following years).- UNION CARBIDE (Graphite Division). Worldwide reorganization. Reengineering of Manufacturing, Sales and Finance. 1993 Strategic Plan. The division maintained its global #1 position.- Other major clients: Automotive & Aerospace: Dassault Aviation, EADS (Aerospatiale, Matra), Hispano-Suiza, KHD, Matra Automobile, Renault, SNECMA, ICI. Electronics: Alcatel, Bull, Hewlett-Packard. Oil & Gas: AGIP, Elf. Other Manufacturing: Alsthom Atlantique, Cabot (Carbon Black), Carnaud Metalbox, Schindler. Services: Aéroports de Paris, Electricité de France, La Redoute Catalogue, Ministère de l’Equipement, SITA. -
Military Engineer (Ingénieur De L'Armement) - Military ServiceDirection Générale De L'Armement Jul 1983 - Jul 1984Paris Cedex 15, Cs 21623, FrSupported 3-star General Sandeau at DGA/DTEn in his mission of evaluating and procuring defense systems. -
LieutenantArmée De L'Air Jul 1983 - Jul 1984FrScientifique du Contingent (Engineer) - French Air Force
Olivier Jarry Skills
Product Marketing
Marketing Management
International Business
Restructuring
Strategic Partnerships
Sales Growth
Mergers
Executive Management
Key Account Management
Start Ups
Forecasting
Biotechnology
Market Research
Business Development
Competitive Analysis
Healthcare
Team Management
Process Improvement
Strategic Planning
Strategy
Organizational Development
Licensing
Management Consulting
Business Planning
Entrepreneurship
Emerging Markets
Program Management
P&l Management
Pharmaceuticals
New Business Development
Cross Functional Team Leadership
Change Management
Product Management
Segmentation
Market Analysis
Strategic Thinking
Acquisition Integration
Marketing Research
Business Strategy
Management
Product Launch
Organizational Design
Due Diligence
Pharmaceutical Industry
Latin America
Corporate Development
Marketing Strategy
Strategic Sourcing
Strategy Development
Joint Ventures
Olivier Jarry Education Details
-
Trium Global Executive MbaInternational Business -
Hec ParisInternational Business
-
The London School Of Economics And Political Science (Lse)International Business
-
Nyu Stern School Of BusinessInternational Business
-
Isae-SupaeroDefense Systems
-
CentralesupélecAerospace
Frequently Asked Questions about Olivier Jarry
What company does Olivier Jarry work for?
Olivier Jarry works for Liberabio
What is Olivier Jarry's role at the current company?
Olivier Jarry's current role is Chief Executive Officer and Co-Founder.
What is Olivier Jarry's email address?
Olivier Jarry's email address is ja****@****ors.com
What is Olivier Jarry's direct phone number?
Olivier Jarry's direct phone number is (914) 703*****
What schools did Olivier Jarry attend?
Olivier Jarry attended Trium Global Executive Mba, Hec Paris, The London School Of Economics And Political Science (Lse), Nyu Stern School Of Business, Isae-Supaero, Centralesupélec.
What skills is Olivier Jarry known for?
Olivier Jarry has skills like Product Marketing, Marketing Management, International Business, Restructuring, Strategic Partnerships, Sales Growth, Mergers, Executive Management, Key Account Management, Start Ups, Forecasting, Biotechnology.
Who are Olivier Jarry's colleagues?
Olivier Jarry's colleagues are Marcos Rúa, Inma Rodríguez, Ludmilla David De Moura, Daniel Perez Estevez.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial